CytomX Therapeutics (CTMX) 2025 Conference June 05, 2025 02:35 PM ET Speaker0 All right. All right. Welcome, everyone, to Jefferies twenty twenty five Global Healthcare Conference. My name is Roger Sung, one of the senior analysts cover SMICHA Biotech in The US. It is my pleasure to have the next fireside chat with Atomic Therapeutics CEO, Sean. Good. Yeah. Good to see you. Speaker1 Pleasure to be here, Roger. Speaker0 Awesome. Maybe before we start, we know you just announced a very exciting data from your ...

SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025, at 2:35 p.m. ET. A live webcast of the presentation will be available on the Events and Presentations page of CytomX’s website at www.cytomx.com. In ...

CytomX Therapeutics (NASDAQ: CTMX ) is a biotech focused on development of novel immunotherapy approaches for different forms of cancer. In my first coverage of them, I expressed a bullish sentiment primarily onI have my PhD in biochemistry and have worked for years analyzing clinical trials and biotech companies. It is my passion to educate everyone possible on the science behind the businesses that we invest in, and it's my mission to help you do your due diligence and not get burned by the pitfalls of in ...

CytomX Therapeutics, Inc. (NASDAQ:CTMX) CX-2051 Phase 1 Interim Clinical Data in Advanced Colorectal Cancer May 12, 2025 8:00 AM ET Company Participants Sean McCarthy - Chairman and CEO Chris Ogden - CFO Wayne Chu - Chief Medical Officer Conference Call Participants Roger Song - Jefferies Anupam Rama - JPMorgan Peter Lawson - Barclays Robert Driscoll - Wedbush Securities Daniel Smith - H.C. Wainwright Operator Good morning, everyone, and thank you for standing by. Welcome to the CytomX Therapeutics CX-2051 ...

CytomX Therapeutics, Inc.‘s CTMX share price was up 94.46% at last check on Monday.The stock surged after the company reported interim Phase 1 data for its EpCAM PROBODY ADC candidate, CX-2051, in advanced, late-line colorectal cancer (CRC).As of April 7, 25 advanced metastatic CRC patients were treated with CX-2051 across dose levels 1 through 5.CX-2051 was administered on a once every three-week schedule (Q3W).The 2.4 mg/kg and 4.8 mg/kg doses were single-patient dose escalation cohorts that were not anti ...

CytomX Therapeutics (CTMX) Q1 2025 Earnings Call May 12, 2025 08:00 AM ET Company Participants Chris Ogden - Chief Financial OfficerSean A. McCarthy - Chairman & CEOWayne Chu - Chief Medical OfficerRobert Driscoll - SVP - Equity ResearchDaniel Smith - Equity Research Associate Conference Call Participants Roger Song - Senior Equity Research AnalystAnupam Rama - AnalystPeter Lawson - Analyst Operator Good morning, everyone, and thank you for standing by. Welcome to the Citemx Therapeutics CX 2,051 phase one ...

CytomX Therapeutics (CTMX) Q1 2025 Earnings Call May 12, 2025 08:00 AM ET Speaker0 Good morning, everyone, and thank you for standing by. Welcome to the Citemx Therapeutics CX 2,051 phase one interim clinical data call. Please be advised that today's call is being recorded. I would now like to hand the call over to your host for today, Chris Ogden, CitemX's chief financial officer. Please go ahead. Speaker1 Thank you. Good morning, and thank you for joining us. Before we begin, I would like to remind everyo ...

SOUTH SAN FRANCISCO, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced the pricing of an underwritten offering of 76,923,076 shares of its common stock at an offering price of $1.30 per share, before underwriting discounts and commissions. All of the shares are being offered by the Company. The gross proceeds from the offering are expected to be approximately $100 million before de ...

财务数据关键指标变化 - 截至2025年3月31日，公司现金、现金等价物和投资总额为7990万美元，而2024年12月31日为1.006亿美元[6] - 2025年第一季度总营收为5090万美元，2024年同期为4150万美元，同比增长约22.65%[7] - 2025年第一季度总运营费用为2830万美元，2024年同期为2980万美元，同比下降约5.03%[8] - 2025年第一季度研发费用为1890万美元，较2024年同期减少320万美元，同比下降约14.51%[9] - 2025年第一季度一般及行政费用为940万美元，较2024年同期增加170万美元，同比增长约21.93%[10] - 2025年2月，阿斯利康T细胞衔接器合作项目取得里程碑，触发向公司支付500万美元[10] - 2025年第一季度实施的临床开发优先级聚焦和成本削减措施，使公司现金可维持至2026年第二季度[10] 各条业务线数据关键指标变化 - CX - 2051已启动7.2mg/kg、8.6mg/kg和10mg/kg剂量扩展，预计2026年第一季度更新至少70名晚期结直肠癌患者的1期数据[4] - CX - 2051计划于2026年上半年启动2期研究[4] - CX - 801在晚期黑色素瘤的1a期转化和生物标志物初始数据预计于2025年下半年公布[10]

- 28% confirmed response rate (5/18) per RECIST v1.1 in unselected patients across doses prioritized for expansion (7.2, 8.6 and 10 mg/kg Q3W) - - 3 of 7 evaluable patients (43%) with confirmed responses at upper expansion dose (10 mg/kg Q3W) - - Median progression free survival of 5.8 months as of April 7th 2025 data cutoff - - Encouraging initial safety profile with no dose limiting toxicities at data cutoff - - Planning Phase 2 study initiation in 1H 2026 - - Conference call on Monday, May 12 at 8:00 a.m ...